Search Results
Mar 02, 2026, 11:30 ET GLP-1 drugs associated with reduced need for emergency care for migraine
For people with chronic migraine, starting GLP-1 drugs for conditions like diabetes may be associated with fewer emergency department visits.A preliminary study has found that people who started GLP-1 drugs were approximately 10% less likely than those who started
More news about: American Academy of Neurology
Feb 28, 2026, 11:00 ET PureHealth Research Launches "Natural GLP-1 Support" Collection, Delivering a Comprehensive Approach to Natural GLP-1 Supplements
How These Natural GLP-1 Supplements Work Across Three PathwaysWhere most competing formulas rely on a single ingredient like berberine alone, GLP ON addresses three distinct phases of GLP-1 activity.
More news about: PureHealth Research LLC
Feb 27, 2026, 18:28 ET Sunlight.com Survey: 1 in 5 Hiring Managers Admit They're Less Likely To Hire Overweight Candidates
weight management medications are showing up in workplace culture. Three in 10 hiring managers say their company encourages employees to use GLP-1 medications for weight management."There's no medical evidence that body weight predicts job performance or correlates with productivity,
More news about: Sunlight
Feb 27, 2026, 11:28 ET Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
MAT December 2025, the total addressable market opportunity for GLP–1 therapies in weight management in the U.S. was approximately USD 127 million.About Glucagon–Like Peptide–1 (GLP–1)Glucagon–like peptide–1 (GLP–1) therapies help regulate blood glucose levels and promote weight
More news about: Cipla USA Inc.
Feb 27, 2026, 09:42 ET PharmaGiant.com Expands Access to Affordable Medications; Announces Upcoming Generic Semaglutide
generic Semaglutide, expected to enter the Canadian market in 2026. This offers a low-cost alternative to expensive brand-name GLP-1 therapies. PharmaGiant.com bridges the affordability gap by connecting U.S. patients with licensed Canadian pharmacies, where regulated pricing
More news about: PharmaGiant.com
Feb 26, 2026, 07:00 ET Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation
first-in-human study.The company completed an initial safety study demonstrating a preliminary safety profile for its implant. In parallel, a large-scale GLP compliant safety study in animals is currently underway and has shown positive interim results. Final results are expected in the 1st half of 2026 and
More news about: Matricelf Ltd.
Feb 26, 2026, 06:30 ET Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week
More news about: Eli Lilly and Company
Feb 25, 2026, 18:07 ET ImpediMed Appoints Medical Technology Commercialization Expert Erik Anderson to Board of Directors
lymphedema (BCRL). The platform also supports structured cancer survivorship programs and medical weight management, including patients on GLP-1 therapies, by providing real-time, whole-body insights. Trusted by healthcare organizations and research institutions worldwide, ImpediMed is redefining
More news about: ImpediMed
Feb 25, 2026, 12:52 ET UFC GYM and NexGen MD Scientific to Launch Strategic Partnership to Expand Longevity Medicine Access
Partnership establishes advanced longevity clinics within UFC GYM locations, delivering integrated peptide, GLP-1, and HRT services to members.DALLAS, Feb. 25, 2026 /PRNewswire/
More news about: NexGen MD Scientific
Feb 25, 2026, 11:41 ET Parker Waichman LLP's Jason Goldstein Appointed to Co-Chair of Plaintiffs' Executive Committee and Federal-State Court Liaison in the GLP-1 NAION Litigation
certain GLP-1 receptor agonist medications are associated with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)—a serious and often irreversible condition that results in optic nerve damage and permanent vision loss. The litigation focuses on widely prescribed GLP-1 drugs,
More news about: Parker Waichman LLP
Feb 25, 2026, 09:00 ET True Rx Health Strategists Collaborates with Waltz Health to Provide Direct-to-Employer, Industry-Leading GLP-1 Pricing
New direct model delivers an in-network pathway for GLP-1 accessWASHINGTON, Ind. and CHICAGO, Feb. 25, 2026 /PRNewswire/ -- True Rx Health Strategists today announced an innovative,
More news about: True Rx Health Strategists
Feb 25, 2026, 08:05 ET Superbrewed Achieves Commercial Production of SB1™ with Döhler; Döhler Ventures Makes Strategic Investment
applications.The launch comes amid a structural shift in dietary demand, including increased focus on sugar reduction and protein-rich nutrition, as GLP-1 medications and broader wellness trends reshape consumer preferences. Superbrewed's platform converts sugar into SB1™, aligning sugar supply with
More news about: Superbrewed Food Inc.
Feb 25, 2026, 08:00 ET PrecisionLife and Ovation identify first potential genetic biomarkers to quantitatively predict GLP-1 efficacy response
identified underlying genetic drivers of GLP-1 efficacy to predict and stratify strong and weak responders within a large real-world population. The insights provide a better understanding of the genetic and biological drivers of GLP-1 responses and provide new biomarkers for drug
More news about: PrecisionLife Ltd; Ovation.io
Feb 25, 2026, 07:40 ET 1 in 5 U.S. blood donors show sign of prediabetes and diabetes
take to manage their diabetes does not disqualify them from donating blood. Q: Can I donate blood while taking GLP-1 medication?A: In most situations, the type of medication you take to manage your diabetes or insulin resistance won't disqualify
More news about: American Red Cross
Feb 25, 2026, 07:00 ET Joint U.S. Commercialization of RedHill's Talicia® Commences
(based on RHB-104's positive Phase 3 Crohn's disease study results); (iii) RHB-102, with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Feb 24, 2026, 12:25 ET GLP China Holdings Limited - ANNOUNCEMENT OF THE SETTLEMENT OF THE OFFER BY THE ISSUER TO THE HOLDERS OF ITS U.S.$700,000,000 2.95 PER CENT. NOTES DUE 2026 (ISIN: XS2314779427; Common Code: 231477942) (Stock Code: 40629) (the "Notes")
content:https://www.prnewswire.com/news-releases/glp-china-holdings-limited---announcement-of-the-settlement-of-the-offer-by-the-issuer-to-the-holders-of-its-us700-000-000-2-95-per-cent-notes-due-2026-isin-xs2314779427-common-code-231477942-stock-code-40629-the-not-302696046.htmlSOURCE
More news about: GLP China Holdings Limited
Feb 24, 2026, 11:40 ET Savings Programs that offer Affordable Access to GLP-1s Available at Kroger
several savings programs, including those from pharmaceutical manufacturers, which may reduce eligible customers' cost of filling certain GLP-1 medications. Combined with Kroger's broad selection of fresh foods, protein‑rich options and personalized support from registered dietitians, the
More news about: The Kroger Co.
Feb 24, 2026, 11:24 ET Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs
Catalyst Awards. The first, led by Professor Carmen Scheibenbogen (Institute of Medical Immunology, Charité), investigates whether semaglutide—a GLP-1 receptor agonist—can improve symptoms and quality of life for people with ME/CFS who are receiving treatment for being overweight. The second, led
More news about: Solve M.E.
Feb 24, 2026, 10:00 ET Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1
Obesity MarketDespite the significant clinical impact of GLP-1 receptor agonists, the majority of the more than 100 million American adults living with obesity remain untreated. While GLP-1 therapies have proven effective for many who initiate and persist on treatment,
More news about: Bloom Science, Inc.
Feb 24, 2026, 09:00 ET More Benefits, Less Confidence: Maven Clinic's Fifth Annual Report Examines the Impact of Fragmented Women's and Family Health Benefits
same after seeing an ad for GLP-1 medications—often before engaging a clinician or employer-sponsored benefit. As a result, expectations for coverage are rising: 53% of employees believe employers should cover HRT, and 47% say employers should cover GLP-1s. In response, 44% of employers have
More news about: Maven Clinic
Feb 24, 2026, 08:32 ET knownwell Demonstrates Improved Obesity Outcomes and Long-Term Durability in First Clinical Outcomes Report
Real-world data from 1,807 patients shows superior weight loss durability and 50% lower leanmass loss compared to published GLP-1 clinical trial benchmarksBOSTON, Feb. 24, 2026 /PRNewswire/
More news about: knownwell
Feb 24, 2026, 08:00 ET Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
health plans or co-insurance benefit designs."Not all GLP-1s are the same. Semaglutide is the active ingredient in Wegovy® and Ozempic®, offering powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with a broad range
More news about: NOVO NORDISK INC.
Feb 24, 2026, 06:40 ET AAFPRS REVEALS THE TRENDS DEFINING FACIAL PLASTIC SURGERY
– one where patients are prioritizing maintenance over correction and making strategic choices that evolve with them over time."GLP-1's Have Altered the Face of Aesthetics – Literally.Weight-loss medications like semaglutide have permanently altered the aesthetic landscape.
More news about: AMERICAN ACADEMY OF FACIAL PLASTIC AND RECONSTRUCTIVE SURGERY
Feb 24, 2026, 00:22 ET Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important
More news about: Sciwind Biosciences Co., Ltd.
Feb 24, 2026, 00:11 ET 先為達生物攜手輝瑞中國，加速偏向型GLP-1商業化進程
View original content:https://www.prnewswire.com/apac/zh/news-releases/glp-1-302695331.htmlSOURCE 杭州先為達生物科技股份有限公司
More news about: 杭州先為達生物科技股份有限公司